Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for late-onset sepsis or necrotizing enterocolitis in preterm infants
2019-002548-26Phase 3Terminated
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in late-onset neonatal sepsis (LONS), necrotizing enterocolitis (NEC) and Immune disorder comparing Pentoxifylline with Placebo (2 arms). Primary endpoint: Survival without disability at 24 months corrected age. Started Oct 2019; status: terminated.
02
Drugs
pentoxifylline
03
Conditions
late-onset neonatal sepsis (LONS)necrotizing enterocolitis (NEC)Immune disorder
Beyond the preview
Go deeper on 2019-002548-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002548-26.